Nam H. Dang

10.3k total citations
194 papers, 7.6k citations indexed

About

Nam H. Dang is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Nam H. Dang has authored 194 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Oncology, 56 papers in Pathology and Forensic Medicine and 46 papers in Molecular Biology. Recurrent topics in Nam H. Dang's work include Peptidase Inhibition and Analysis (68 papers), Lymphoma Diagnosis and Treatment (51 papers) and Chronic Lymphocytic Leukemia Research (24 papers). Nam H. Dang is often cited by papers focused on Peptidase Inhibition and Analysis (68 papers), Lymphoma Diagnosis and Treatment (51 papers) and Chronic Lymphocytic Leukemia Research (24 papers). Nam H. Dang collaborates with scholars based in United States, Japan and United Kingdom. Nam H. Dang's co-authors include Chikao Morimoto, Kei Ohnuma, Yoshihiro Torimoto, Satoshi Iwata, Barbara Pro, S F Schlossman, Osamu Hosono, Stuart F. Schlossman, Felipe Samaniego and Jorge Romaguera and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Nam H. Dang

192 papers receiving 7.5k citations

Peers

Countries citing papers authored by Nam H. Dang

Since Specialization

Citations

This map shows the geographic impact of Nam H. Dang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nam H. Dang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nam H. Dang more than expected).

Fields of papers citing papers by Nam H. Dang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nam H. Dang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nam H. Dang. The network helps show where Nam H. Dang may publish in the future.

Co-authorship network of co-authors of Nam H. Dang

This figure shows the co-authorship network connecting the top 25 collaborators of Nam H. Dang. A scholar is included among the top collaborators of Nam H. Dang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nam H. Dang. Nam H. Dang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An abnormal increase in CD26(−)CD28(−) cytotoxic effector CD4 and CD8 T cell populations in patients with systemic lupus erythematosus 2024 ·International Immunology ·Ryo Hatano, Hayato Nakamura, Ayako Yamamoto, Haruna Otsuka, Takumi Itoh, (unknown), (unknown), (unknown), Yuta Hasegawa, Tsutomu Sato, Nam H. Dang, Kei Ohnuma, Shinji Morimoto, Iwao Sekigawa, Tomonori Ishii, Chikao Morimoto	0
2	Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies 2023 ·Cells ·Eiji Kobayashi, Yusuke Kamihara, (unknown), Akinori Wada, Shohei Kikuchi, Ryo Hatano, (unknown), (unknown), Tatsuhiko Ozawa, Yuichi Adachi, Hiroyuki Kishi, Nam H. Dang, Taketo Yamada, Yoshihiro Hayakawa, Chikao Morimoto, Tsutomu Sato	5
3	A Novel Mechanism for Bone Loss: Platelet Count Negatively Correlates with Bone Mineral Density via Megakaryocyte-Derived RANKL 2023 ·International Journal of Molecular Sciences ·Shohei Kikuchi, Akinori Wada, Yusuke Kamihara, I Yamamoto, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Nam H. Dang, Tsutomu Sato	2
4	Evaluating the impact of Khanh Son power plant on Danang Distribution Network 2021 ·International Journal of Emerging Electric Power Systems ·Thi Minh Tu Bui, (unknown), (unknown), (unknown), (unknown), Nam H. Dang	1
5	Reduction of immunosuppression for post-transplant lymphoproliferative disorder (PTLD): a single-center experience of allograft survival outcomes 2020 ·Leukemia & lymphoma ·(unknown), Aaron J Franke, William Paul Skelton, Rohit Bishnoi, Chintan Shah, Nam H. Dang, (unknown)	6
6	Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer 2016 ·ACS Chemical Biology ·(unknown), (unknown), Ranjala Ratnayake, Pamela A. Havre, (unknown), Nam H. Dang, Valerie J. Paul, Thomas J. Carney, Long H. Dang, Hendrik Luesch	27
7	Long term results of a phase 2 study of vincristine sulfate liposome injection ( M arqibo ^® ) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐ H odgkin lymphomas 2013 ·British Journal of Haematology ·Fredrick B. Hagemeister, Maria Alma Rodriguez, Steven R. Deitcher, Anas Younes, Luis Fayad, André Goy, Nam H. Dang, Arthur Forman, Peter McLaughlin, Leonard Jeffrey Medeiros, Barbara Pro, Jorge Romaguera, Felipe Samaniego, Jeffrey A. Silverman, Andreas H. Sarris, Fernando Cabanillas	24
8	Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab 2013 ·Journal of Clinical Oncology ·Luis Fayad, Fritz Offner, Mitchell R. Smith, Gregor Verhoef, Peter Johnson, Jonathan L. Kaufman, A. Z. S. Rohatiner, Anjali S. Advani, James M. Foran, Georg Heß, Bertrand Coiffier, Myron S. Czuczman, Eva Giné, Simon Durrant, Michelle Kneissl, Kenneth T. Luu, Steven Y. Hua, Joseph Boni, Erik Vandendries, Nam H. Dang	119
9	CD26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma 2012 ·Clinical Cancer Research ·Keisuke Aoe, Vishwa Jeet Amatya, Nobukazu Fujimoto, Kei Ohnuma, Osamu Hosono, Akio Hiraki, Masanori Fujii, Taketo Yamada, Nam H. Dang, Yukio Takeshima, Kouki Inai, Takumi Kishimoto, Chikao Morimoto	49
10	Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma 2012 ·Clinical Cancer Research ·Andres Forero‐Torres, Sven de Vos, Brad Pohlman, (unknown), Damien M. Cronier, Nam H. Dang, Susan P. Carpenter, Barrett W. Allan, (unknown), Christopher A. Slapak, Mitchell R. Smith, Brian K. Link, James E. Wooldridge, Kristen N. Ganjoo	54
11	Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer 2012 ·Clinical Cancer Research ·Shunsuke Kondo, Satoshi Iwata, Taketo Yamada, Yusuke Inoue, (unknown), (unknown), (unknown), (unknown), Hiroto Yamazaki, Osamu Hosono, Hiroshi Kawasaki, Hirotoshi Tanaka, Yuichiro Hayashi, Michiie Sakamoto, Kazunori Kamiya, Nam H. Dang, Chikao Morimoto	40
12	An in vivo patient-derived model of endogenous IDH1-mutant glioma 2011 ·Neuro-Oncology ·H. Artee Luchman, (unknown), Nam H. Dang, Michael Blough, (unknown), John J. Kelly, Shaun A. Nguyen, Jennifer A. Chan, Aalim M. Weljie, J. G. Cairncross, Sarah A. Weiss	134
13	Aqueous extract of Carica papaya leaves exhibits anti-tumor activity and immunomodulatory effects 2009 ·Journal of Ethnopharmacology ·Noriko Otsuki, Nam H. Dang, (unknown), Akira Kondo, Satoshi Iwata, Chikao Morimoto	294
14	Hypoxia-Inducible Factor-1 Target Genes as Indicators of Tumor Vessel Response to Vascular Endothelial Growth Factor Inhibition 2008 ·Cancer Research ·Duyen T. Dang, Sang Y. Chun, Kyunghee Burkitt, Masako Abe, Shaowei Chen, Pamela A. Havre, Nicola J. Mabjeesh, Elisabeth I. Heath, Nicholas J. Vogelzang, Marcia Cruz‐Correa, Douglas W. Blayney, William D. Ensminger, Brad St. Croix, Nam H. Dang, Long H. Dang	62
15	Recovery of natural killer cell counts after one course of CHOP chemotherapy is diminished in patients older than 60 compared to patients younger than 60. 2004 ·Cancer Research ·(unknown), Maria Alma Rodriguez, Fernando Cabanillas, Nam H. Dang, Peter McLaughlin, Fredrick B. Hagemeister, Barbara Pro, Jorge Romaguera, Anas Younes, Elizabeth A. Grimm	2
16	HTLV-I Tax induces and associates with Crk-associated substrate lymphocyte type (Cas-L) 2004 ·Oncogene ·Satoshi Iwata, (unknown), A. Yamakawa, Takahiro Sasaki, Takatsune Shimizu, Osamu Hosono, Hiroshi Kawasaki, Hirotoshi Tanaka, Nam H. Dang, Toshiki Watanabe, Naomichi Arima, Chikao Morimoto	18
17	SS-A/Ro52, an Autoantigen Involved in CD28-Mediated IL-2 Production 2003 ·The Journal of Immunology ·Tomonori Ishii, Kei Ohnuma, Akikazu Murakami, Naruhiko Takasawa, Tadanori Yamochi, Satoshi Iwata, Masahiko Uchiyama, Nam H. Dang, Hirotoshi Tanaka, Chikao Morimoto	44
18	T‐large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition 2003 ·British Journal of Haematology ·Nam H. Dang, Ugur Aytac, Kazuya Sato, Susan O’Brien, Jos Melenhorst, Chikao Morimoto, A. John Barrett, Jeffrey J. Molldrem	27
19	Soluble CD26/Dipeptidyl Peptidase IV Induces T Cell Proliferation Through CD86 Up-Regulation on APCs 2001 ·The Journal of Immunology ·Kei Ohnuma, Yasuhiko Munakata, Tomonori Ishii, Satoshi Iwata, Seiji Kobayashi, Osamu Hosono, Hiroshi Kawasaki, Nam H. Dang, Chikao Morimoto	51
20	Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family. 1990 ·The Journal of Experimental Medicine ·Nam H. Dang, Yoshihiro Torimoto, S F Schlossman, Chikao Morimoto	164

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact